Skip to main content
OpenTrials
Completed

NCT Number: NCT02983253

Immunmodulation in Patients With HHT

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hereditary Haemorrhagic Telangiectasia (HHT) Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Telangiectasia, Hereditary Hemorrhagic Telangiectasis Vascular Diseases Vascular Malformations

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Essen

Essen, 45147, Germany

About this study

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Literature and the investigators' observation suggest that HHT is often associated with higher frequency of infectious diseases. This might be a hint for a immunocompromised situation.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 18 or over, HHT

Exclusion criteria

  • Unable to provide informed consent

Treatment and study plan

blood sample

Other

none, only laboratory tests on blood serum

Primary outcomes

  1. Amounts of leucocytes in patients with HHT

    Time frame: November 2016 - December 2018

Secondary outcomes

  1. Differences in distribution of leucocytes in patients with HHT

    Time frame: November 2016 - December 2018

Other outcomes

  1. Functional properties of leucocytes in patients with HHT

    Time frame: November 2016 - December 2018

  2. Differences in size of leucocytes in patients with HHT

    Time frame: November 2016 - December 2018

Sponsors and collaborators

Lead sponsor

University Hospital, Essen

Other

Registry information

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Dec 6, 2016
Registry last updated
Dec 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.